CN110876749A - Application of chelerythrine in inhibiting growth of multiple drug-resistant serratia marcescens - Google Patents
Application of chelerythrine in inhibiting growth of multiple drug-resistant serratia marcescens Download PDFInfo
- Publication number
- CN110876749A CN110876749A CN201911329153.XA CN201911329153A CN110876749A CN 110876749 A CN110876749 A CN 110876749A CN 201911329153 A CN201911329153 A CN 201911329153A CN 110876749 A CN110876749 A CN 110876749A
- Authority
- CN
- China
- Prior art keywords
- serratia marcescens
- resistant
- chelerythrine
- multiple drug
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of chelerythrine in inhibiting the growth of multiple drug-resistant serratia marcescens, and provides an inhibition effect of chelerythrine on multiple drug-resistant serratia marcescens according to the fact that the chelerythrine has a good in-vitro killing effect on the multiple drug-resistant serratia marcescens and can inhibit the growth of the multiple drug-resistant serratia marcescens, the minimum sterilization concentration is 30-250 mu g/mL, and the minimum inhibition concentration is 15-125 mu g/mL.
Description
Technical Field
The invention relates to the field of medicines, and in particular relates to application of chelerythrine in inhibition of growth of multiple drug-resistant serratia marcescens.
Background
Serratia marcescens (Serratia marcescens), a gram-negative bacterium of Serratia of Enterobacteriaceae, can cause various infections. Serratia marcescens is currently known to cause infections of the eye, lungs, urinary tract and bloodstream. Recent reports have shown that this pathogen is present in 2.5% -7.7% of catheter-related infections. In recent years, the drug resistance rate and the clinical separation rate of carbapenem-resistant serratia marcescens gradually rise, which brings great challenges to hospital infection prevention and control and clinical anti-infection treatment work.
Chelerythrine is a natural benzophenanthridine alkaloid extracted from plants such as semen Strychni, radix rehmanniae, and Canadian red Cephalotaxus fortunei. Chelerythrine has wide biological activity and plays an important role in resisting tumors, inflammation and diabetes. Studies have shown that chelerythrine has antibacterial activity. The document reports that chelerythrine has better inhibition effect on the growth of hyphae of gentian blight bacteria, corn small spot bacteria, walnut leaf blight bacteria, tomato blight bacteria, pumpkin blight bacteria and curvularia lunata. It is also reported in the literature that chelerythrine inhibits the growth of streptococcus mutans by inhibiting its cell division, and has a significant effect on the structure of capsule, cell wall, cell membrane, etc. Chinese patent reports the application of chelerythrine in treating poultry-resistant colibacillosis (CN106138054A), wherein the colibacillosis is Escherichia coli in Enterobacteriaceae. At present, no document reports that chelerythrine has an antibacterial effect on multiple drug-resistant serratia marcescens.
Disclosure of Invention
The invention aims to solve the problem of drug resistance in current clinical medicine and provides application of chelerythrine in inhibition of growth of multiple drug-resistant serratia marcescens.
In order to achieve the purpose, the invention adopts the technical scheme that:
the drug resistance of the serratia marcescens to the antibiotics is determined by a trace double dilution method, and then the Minimum Inhibitory Concentration (MIC) and the Minimum Bactericidal Concentration (MBC) of chelerythrine to the serratia marcescens are determined. The results show that: the chelerythrine has good bacteriostatic action on the multiple drug-resistant serratia marcescens, and can be used for inhibiting the growth of the multiple drug-resistant serratia marcescens.
Preferably, the multidrug-resistant Serratia marcescens is human Serratia marcescens which is resistant to a plurality of antibiotics in ampicillin, ampicillin/sulbactam, cefazolin, cefotetan, ceftriaxone, ceftazidime, piperacillin/tazobactam, compound neodimine, cefepime, aztreonam, gentamicin, ertapenem, imipenem, tobramycin, amikacin, ciprofloxacin, nitrofurantoin and levofloxacin.
Preferably, the multidrug-resistant Serratia marcescens is selected from the group consisting of Serratia marcescens of human origin resistant to ampicillin, ampicillin/sulbactam, cefazolin, cefotetan, ceftriaxone, ceftazidime, cefepime, ertapenem, aztreonam, tobramycin, amikacin, ciprofloxacin, levofloxacin, sulfamethoxazole, piperacillin/tazobactam and nitrofurantoin.
Preferably, the minimum bactericidal concentration of the chelerythrine is 30-250 mug/mL, and the minimum bacteriostatic concentration of the chelerythrine is 15-125 mug/mL.
The invention has the beneficial effects that:
the invention starts from the existing medicinal plant resource library, develops a potential drug-resistant bacteria inhibitor, finds that the non-antibiotic compound chelerythrine can effectively inhibit the growth of the multiple drug-resistant serratia marcescens based on the research on the effect of the chelerythrine on the multiple drug-resistant serratia marcescens, provides a new thought and source for the research, development and application of the multiple drug-resistant serratia marcescens inhibitor, and has wide application value in the fields of medicine and the like.
Furthermore, the invention defines the inhibition effect of chelerythrine on the multiple drug-resistant serratia marcescens, and the chelerythrine can be used as an antibiotic substitute to effectively relieve or solve the drug-resistant and infection problems of the multiple drug-resistant serratia marcescens and reduce the fatality rate.
Detailed Description
The present invention will be described in further detail with reference to examples. The examples are only for explaining the present invention and do not limit the scope of protection of the present invention.
1. Drug sensitivity test of Serratia marcescens
The invention takes a plurality of strains of humanized Serratia marcescens (strain samples are taken from Ningbo women hospitals) as starting strains, and selects 18 common antibiotics of ampicillin, ampicillin/sulbactam, cefazolin, cefotetan, ceftriaxone, ceftazidime, piperacillin/tazobactam, compound sulfamethoxazole, cefepime, aztreonam, gentamicin, ertapenem, imipenem, tobramycin, amikacin, ciprofloxacin, nitrofurantoin and levofloxacin for testing.
And (3) selecting and culturing the pure colonies for 18-24 hours, uniformly dissolving the pure colonies in 2-5 mL of sterile physiological saline, and adjusting the turbidity of the pure colonies to be equal to that of a 0.5 McLeod turbiditube. Adding antibiotics, bacterial liquid and TSB liquid culture medium into a 96-well culture plate by using a test tube double dilution method for overnight culture, and measuring the Minimum Inhibitory Concentration (MIC) of the antibiotics to Serratia marcescens by using a microplate reader. The three liquid medicine groups with different concentrations are parallel, so that the reliability of experimental data is ensured. The bacteriostatic result is judged according to the national standard administration committee of the united states clinical laboratory (CLSl2017), and the judgment standard is shown in table 1. The results are shown in Table 2 and show that Serratia marcescens 1 is resistant to 16 antibiotics (2 mediators), and thus is the subject of the next experiment.
TABLE 1 results of the national Committee for standardization management of the clinical laboratory (CLSl2017) standards
TABLE 2 MIC results of drug sensitivity test of human Serratia marcescens
2. Inhibition effect of chelerythrine on multiple drug-resistant strains
In order to fully consider the medication safety, the invention takes chelerythrine which is a single active component as a research object, and takes a standard strain (ATCC-14041, sensitive to antibiotics such as cephalexin, kanamycin, cephalosporin, gentamicin, neomycin, tetracycline and the like) as a reference to research the drug resistance inhibition effect. Selecting and culturing the pure bacterial colonies for 18-24 h, uniformly dissolving the pure bacterial colonies in 2-5 mL of TSB liquid culture medium, adjusting the turbidity of the TSB liquid culture medium to be equal to that of a 0.5 McLeod turbiditube, and measuring the OD of the TSB liquid culture medium by using an enzyme-labeling instrument600The value is obtained. Preparing chelerythrine with concentration of 1000 μ g/mL with dimethyl sulfoxide as medicinal liquid, adding the medicinal liquid, bacterial liquid and TSB liquid culture medium into 96-well by test tube double dilution method, and culturingThe plates are cultured overnight, and three liquid medicine groups with different concentrations are parallel to ensure the reliability of experimental data.
And (3) determining the Minimum Inhibitory Concentration (MIC) of chelerythrine to the multiple drug-resistant Serratia marcescens by using a microplate reader. And transferring the culture solution with the concentration of the MIC diluted by the former drug to a sterile TSA solid culture medium for continuous culture, observing whether a single colony is generated, and if not, determining the concentration as the Minimum Bactericidal Concentration (MBC) of chelerythrine to the multidrug-resistant serratia marcescens, wherein the experimental results are shown in Table 3.
TABLE 3 results of chelerythrine inhibition of multidrug-resistant Serratia marcescens
As shown in Table 3, chelerythrine has a good inhibitory effect on drug-resistant Serratia marcescens with multiple drug resistance, wherein MIC is 125 mu g/mL, and MBC is 250 mu g/mL, against ampicillin, ampicillin/sulbactam, cefazolin, cefotetan, ceftriaxone, ceftazidime, cefepime, ertapenem, aztreonam, tobramycin, amikacin, ciprofloxacin, levofloxacin, sulfamethoxazole, piperacillin/tazobactam, and nitrofurantoin. The results show that chelerythrine not only has the bacteriostatic action on the Serratia marcescens reference strain ATCC-14041, but also has the bacteriostatic action on the multiple drug-resistant Serratia marcescens (such as the No. 1 strain) in the invention.
According to the experimental results, by combining the characteristics of wide sources of Chinese herbal medicines, less adverse reaction, difficult generation of drug resistance and the like, the active single-product component chelerythrine can be obtained, the inhibition effect is directly exerted on clinically main multiple drug-resistant serratia marcescens, the infection problem of the multiple drug-resistant serratia marcescens can be effectively relieved or solved, the mortality rate of diseases is reduced, scientific basis is provided for researching clinically separated bacteriostatic agents of the serratia marcescens, and new ideas and sources are provided for developing drugs and antibiotic substitutes for inhibiting the multiple drug-resistant serratia marcescens.
Claims (10)
1. Application of chelerythrine in inhibiting growth of multiple drug-resistant serratia marcescens is provided.
2. Use according to claim 1, characterized in that: the multiple drug-resistant serratia marcescens is humanized serratia marcescens.
3. Use according to claim 1, characterized in that: the drug resistance of the serratia marcescens is determined by a micro-double dilution method.
4. Use according to claim 1, characterized in that: the antibiotic which is tolerated by the multi-drug resistant serratia marcescens is selected from a plurality of ampicillin, ampicillin/sulbactam, cefazolin, cefotetan, ceftriaxone, ceftazidime, piperacillin/tazobactam, compound neodimine, cefepime, aztreonam, gentamicin, ertapenem, imipenem, tobramycin, amikacin, ciprofloxacin, nitrofurantoin and levofloxacin.
5. Use according to claim 1, characterized in that: the multiple drug-resistant Serratia marcescens is selected from Serratia marcescens which is resistant to ampicillin, ampicillin/sulbactam, cefazolin, cefotetan, ceftriaxone, ceftazidime, cefepime, ertapenem, aztreonam, tobramycin, amikacin, ciprofloxacin, levofloxacin, compound sulfamethoxazole, piperacillin/tazobactam and nitrofurantoin.
6. Use according to claim 5, characterized in that: the minimum bactericidal concentration of the chelerythrine to the multidrug-resistant serratia marcescens is 30-250 mu g/mL, and the minimum bacteriostatic concentration is 15-125 mu g/mL.
7. Use according to claim 1, characterized in that: the chelerythrine has in vitro killing effect on multiple drug-resistant serratia marcescens and can inhibit in vitro growth of multiple drug-resistant serratia marcescens.
8. Application of chelerythrine in preparing medicine for resisting multiple drug-resistant serratia marcescens is provided.
9. Use according to claim 8, characterized in that: the multiple drug-resistant serratia marcescens is humanized serratia marcescens.
10. Use according to claim 8, characterized in that: the multiple drug-resistant serratia marcescens is selected from serratia marcescens resistant to various antibiotics in ampicillin, ampicillin/sulbactam, cefazolin, cefotetan, ceftriaxone, ceftazidime, piperacillin/tazobactam, compound neodimine, cefepime, aztreonam, gentamicin, ertapenem, imipenem, tobramycin, amikacin, ciprofloxacin, nitrofurantoin and levofloxacin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911329153.XA CN110876749B (en) | 2019-12-20 | 2019-12-20 | Application of chelerythrine in inhibiting growth of multi-drug resistant serratia marcescens |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911329153.XA CN110876749B (en) | 2019-12-20 | 2019-12-20 | Application of chelerythrine in inhibiting growth of multi-drug resistant serratia marcescens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110876749A true CN110876749A (en) | 2020-03-13 |
| CN110876749B CN110876749B (en) | 2023-06-23 |
Family
ID=69731803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911329153.XA Active CN110876749B (en) | 2019-12-20 | 2019-12-20 | Application of chelerythrine in inhibiting growth of multi-drug resistant serratia marcescens |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110876749B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101428026A (en) * | 2008-11-10 | 2009-05-13 | 成都军区昆明总医院 | New use of 8-substituted dihydrobenzene-[C]phenanthridine alkaloids in producing anti-drug-fast bacteria medicament |
| US20120022061A1 (en) * | 2009-01-15 | 2012-01-26 | Lavoie Edmond J | Benzo [c] phenanthridines as antimicrobial agents |
-
2019
- 2019-12-20 CN CN201911329153.XA patent/CN110876749B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101428026A (en) * | 2008-11-10 | 2009-05-13 | 成都军区昆明总医院 | New use of 8-substituted dihydrobenzene-[C]phenanthridine alkaloids in producing anti-drug-fast bacteria medicament |
| US20120022061A1 (en) * | 2009-01-15 | 2012-01-26 | Lavoie Edmond J | Benzo [c] phenanthridines as antimicrobial agents |
Non-Patent Citations (2)
| Title |
|---|
| NAN HE: "Antibacterial mechanism of chelerythrine isolated from root of Toddalia asiatica (Linn) Lam", 《BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE》 * |
| 刘星宇等: "调节生物被膜化合物的研究进展", 《生物工程学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110876749B (en) | 2023-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021068614A1 (en) | Application of honokiol and magnolol in preparing mcr-1 enzyme inhibitor | |
| CN110652512B (en) | Application of crizotinib in preparation of anti-gram-positive-bacteria drugs | |
| CN110251526A (en) | Paeoniflorin is inhibiting the application in the growth of Carbapenem-resistant parapneumonia klebsiella | |
| CN115737624B (en) | Application of natural medicine in preparation of anti-Acinetobacter baumannii medicine | |
| Hubka et al. | In vitro susceptibility of canine and feline Escherichia coli to fosfomycin | |
| CN101543499B (en) | Application of natural compound ursolic acid on antibiosis | |
| CN111939156B (en) | Combined antibacterial pharmaceutical composition and application thereof | |
| CN110279679B (en) | Application of citral in inhibition of growth of multiple drug-resistant enterobacter cloacae | |
| CN110876749A (en) | Application of chelerythrine in inhibiting growth of multiple drug-resistant serratia marcescens | |
| CN110960545A (en) | Application of punicalagin in inhibiting growth of multidrug-resistant klebsiella pneumoniae | |
| CN110934859B (en) | Application of luteolin in inhibition of growth of multidrug-resistant providencia rettgeri | |
| CN110215445B (en) | Application of vanillic acid in inhibiting growth of multiple drug-resistant enterobacter hopcalis | |
| CN110946870A (en) | Antibacterial pharmaceutical composition and application thereof | |
| CN110870865B (en) | Application of sanguinarine in inhibition and removal of multiple-drug-resistant providencia rettgeri biofilm | |
| CN111135173B (en) | Application of chelerythrine in inhibition and removal of multiple-drug-resistant providencia rettgeri biofilm | |
| CN110946862B (en) | Application of sanguinarine in inhibition of growth of multiple drug-resistant enterobacter hopcalis | |
| CN111000845B (en) | Application of chelerythrine in inhibition of growth of multidrug-resistant providencia rettgeri | |
| CN110772518A (en) | Application of sanguinarine in inhibiting growth of staphylococcus lugdunensis | |
| CN110934870A (en) | Application of sanguinarine in inhibition of growth of multidrug-resistant providencia rettgeri | |
| CN110934871B (en) | Application of sanguinarine in inhibiting growth of multiple drug-resistant serratia marcescens | |
| CN108113980B (en) | Application of deoxyschizandrin in inhibiting growth of multi-drug-resistant escherichia coli | |
| CN110237058B (en) | Application of citral in inhibition of growth of multidrug-resistant enterobacter heumakii | |
| CN111000841A (en) | Application of luteolin in inhibition of growth of multiple drug-resistant enterobacter cloacae | |
| CN110215446B (en) | Application of vanillic acid in inhibiting growth of multiple drug-resistant enterobacter cloacae | |
| CN110946863A (en) | Application of chelerythrine in inhibiting growth of staphylococcus lugdunensis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |